{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T04:05:30Z","timestamp":1794197130676,"version":"4.8.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-NS050895"],"award-info":[{"award-number":["R01-NS050895"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AG020241"],"award-info":[{"award-number":["R01-AG020241"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01-AG060965"],"award-info":[{"award-number":["U01-AG060965"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21-NS101504"],"award-info":[{"award-number":["R21-NS101504"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AG061895"],"award-info":[{"award-number":["R01-AG061895"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RF1-AG048099"],"award-info":[{"award-number":["RF1-AG048099"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AG055524"],"award-info":[{"award-number":["R01-AG055524"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AG056303"],"award-info":[{"award-number":["R01-AG056303"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50-AG016573"],"award-info":[{"award-number":["P50-AG016573"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01-AI061142"],"award-info":[{"award-number":["U01-AI061142"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHS-N272201400053C"],"award-info":[{"award-number":["HHS-N272201400053C"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHS-N272200800039C"],"award-info":[{"award-number":["HHS-N272200800039C"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alzheimer disease (AD) is characterized by the accumulation of beta-amyloid (A\u03b2) plaques and neurofibrillary tangles composed of hyperphosphorylated tau, which together lead to neurodegeneration and cognitive decline. Current therapeutic approaches have primarily aimed to reduce pathological aggregates of either A\u03b2 or tau, yet phase 3 clinical trials of these approaches have thus far failed to delay disease progression in humans. Strong preclinical evidence indicates that these two abnormally aggregated proteins interact synergistically to drive downstream neurodegeneration. Therefore, combinatorial therapies that concurrently target both A\u03b2 and tau might be needed for effective disease modification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A combinatorial vaccination approach was designed to concurrently target both A\u03b2 and tau pathologies. Tau22\/5xFAD (T5x) bigenic mice that develop both pathological A\u03b2 and tau aggregates were injected intramuscularly with a mixture of two MultiTEP epitope vaccines: AV-1959R and AV-1980R, targeting A\u03b2 and tau, respectively, and formulated in Advax\n                      <jats:sup>CpG<\/jats:sup>\n                      , a potent polysaccharide adjuvant. Antibody responses of vaccinated animals were measured by ELISA, and neuropathological changes were determined in brain homogenates of vaccinated and control mice using ELISA and Meso Scale Discovery (MSD) multiplex assays.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      T5x mice immunized with a mixture of A\u03b2- and tau-targeting vaccines generated high A\u03b2- and tau-specific antibody titers that recognized senile plaques and neurofibrillary tangles\/neuropil threads in human AD brain sections. Production of these antibodies in turn led to significant reductions in the levels of soluble and insoluble total tau, and hyperphosphorylated tau as well as insoluble A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      , within the brains of bigenic T5x mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      AV-1959R and AV-1980R formulated with Advax\n                      <jats:sup>CpG<\/jats:sup>\n                      adjuvant are immunogenic and therapeutically potent vaccines that in combination can effectively reduce both of the hallmark pathologies of AD in bigenic mice. Taken together, these findings warrant further development of this vaccine technology for ultimate testing in human AD.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-019-0556-2","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T15:03:56Z","timestamp":1576595036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Testing a MultiTEP-based combination vaccine to reduce A\u03b2 and tau pathology in Tau22\/5xFAD bigenic mice"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8554-6456","authenticated-orcid":false,"given":"Hayk","family":"Davtyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armine","family":"Hovakimyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepideh","family":"Kiani Shabestari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatevik","family":"Antonyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan A.","family":"Coburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Zagorski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gor","family":"Chailyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Petrushina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Svystun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Danhash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Petrovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Cribbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Agadjanyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Blurton-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahit","family":"Ghochikyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"key":"556_CR1","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/mp.2016.37","volume":"22","author":"TA Pascoal","year":"2017","unstructured":"Pascoal TA, Mathotaarachchi S, Mohades S, Benedet AL, Chung CO, Shin M, Wang S, Beaudry T, Kang MS, Soucy JP, et al. Amyloid-beta and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer\u2019s disease. Mol Psychiatry. 2017;22:306\u201311.","journal-title":"Mol Psychiatry"},{"key":"556_CR2","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jalz.2016.11.005","volume":"13","author":"TA Pascoal","year":"2017","unstructured":"Pascoal TA, Mathotaarachchi S, Shin M, Benedet AL, Mohades S, Wang S, Beaudry T, Kang MS, Soucy JP, Labbe A, et al. Synergistic interaction between amyloid and tau predicts the progression to dementia. Alzheimers Dement. 2017;13:644\u201353.","journal-title":"Alzheimers Dement"},{"key":"556_CR3","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1093\/brain\/awx243","volume":"140","author":"A Bejanin","year":"2017","unstructured":"Bejanin A, Schonhaut DR, La Joie R, Kramer JH, Baker SL, Sosa N, Ayakta N, Cantwell A, Janabi M, Lauriola M, et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer\u2019s disease. Brain. 2017;140:3286\u2013300.","journal-title":"Brain"},{"key":"556_CR4","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","volume":"71","author":"PT Nelson","year":"2012","unstructured":"Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71:362\u201381.","journal-title":"J Neuropathol Exp Neurol"},{"key":"556_CR5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"556_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207\u201316.","journal-title":"Lancet Neurol"},{"key":"556_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack Jr","year":"2010","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol. 2010;9:119\u201328.","journal-title":"Lancet Neurol"},{"key":"556_CR8","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.neuron.2016.09.055","volume":"92","author":"SK Kaufman","year":"2016","unstructured":"Kaufman SK, Sanders DW, Thomas TL, Ruchinskas AJ, Vaquer-Alicea J, Sharma AM, Miller TM, Diamond MI. Tau prion strains dictate patterns of cell pathology, progression rate, and regional vulnerability in vivo. Neuron. 2016;92:796\u2013812.","journal-title":"Neuron"},{"issue":"8","key":"556_CR9","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","volume":"76","author":"Bernard J. Hanseeuw","year":"2019","unstructured":"Hanseeuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA, Cosio DMO, Farrell M, Quiroz YT, Mormino EC, et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 2019;76(8):986.","journal-title":"JAMA Neurology"},{"key":"556_CR10","doi-asserted-by":"publisher","first-page":"28912","DOI":"10.1038\/srep28912","volume":"6","author":"H Davtyan","year":"2016","unstructured":"Davtyan H, Zagorski K, Rajapaksha H, Hovakimyan A, Davtyan A, Petrushina I, Kazarian K, Cribbs DH, Petrovsky N, Agadjanyan MG, Ghochikyan A. Alzheimer\u2019s disease Advax (CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Abeta pathological molecules. Sci Rep. 2016;6:28912.","journal-title":"Sci Rep"},{"key":"556_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s40478-016-0336-1","volume":"4","author":"W Chen","year":"2016","unstructured":"Chen W, Abud EA, Yeung ST, Lakatos A, Nassi T, Wang J, Blum D, Buee L, Poon WW, Blurton-Jones M. Increased tauopathy drives microglia-mediated clearance of beta-amyloid. Acta Neuropathol Commun. 2016;4:63.","journal-title":"Acta Neuropathol Commun"},{"key":"556_CR12","doi-asserted-by":"publisher","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","volume":"26","author":"H Oakley","year":"2006","unstructured":"Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer\u2019s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129\u201340.","journal-title":"J Neurosci"},{"key":"556_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2353\/ajpath.2006.060002","volume":"169","author":"K Schindowski","year":"2006","unstructured":"Schindowski K, Bretteville A, Leroy K, Begard S, Brion JP, Hamdane M, Buee L. Alzheimer\u2019s disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol. 2006;169:599\u2013616.","journal-title":"Am J Pathol"},{"key":"556_CR14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jalz.2013.04.505","volume":"10","author":"CF Evans","year":"2014","unstructured":"Evans CF, Davtyan H, Petrushina I, Hovakimyan A, Davtyan A, Hannaman D, Cribbs DH, Agadjanyan MG, Ghochikyan A. Epitope-based DNA vaccine for Alzheimer\u2019s disease: translational study in macaques. Alzheimers Dement. 2014;10:284\u201395.","journal-title":"Alzheimers Dement"},{"key":"556_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/gt.2009.140","volume":"17","author":"H Davtyan","year":"2010","unstructured":"Davtyan H, Mkrtichyan M, Movsesyan N, Petrushina I, Mamikonyan G, Cribbs DH, Agadjanyan MG, Ghochikyan A. DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. Gene Ther. 2010;17:261\u201371.","journal-title":"Gene Ther"},{"key":"556_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13024-017-0172-1","volume":"12","author":"MG Agadjanyan","year":"2017","unstructured":"Agadjanyan MG, Zagorski K, Petrushina I, Davtyan H, Kazarian K, Antonenko M, Davis J, Bon C, Blurton-Jones M, Cribbs DH, Ghochikyan A. Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency. Mol Neurodegener. 2017;12:33.","journal-title":"Mol Neurodegener"},{"key":"556_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.nbd.2016.05.016","volume":"94","author":"B Combs","year":"2016","unstructured":"Combs B, Hamel C, Kanaan NM. Pathological conformations involving the amino terminus of tau occur early in Alzheimer\u2019s disease and are differentially detected by monoclonal antibodies. Neurobiol Dis. 2016;94:18\u201331.","journal-title":"Neurobiol Dis"},{"key":"556_CR18","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1371\/journal.pone.0002124","volume":"3","author":"N Movsesyan","year":"2008","unstructured":"Movsesyan N, Ghochikyan A, Mkrtichyan M, Petrushina I, Davtyan H, Olkhanud PB, Head E, Biragyn A, Cribbs DH, Agadjanyan MG. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine- a novel immunotherapeutic strategy. PLoS One. 2008;3:e21\u20134.","journal-title":"PLoS One"},{"key":"556_CR19","doi-asserted-by":"publisher","first-page":"190","DOI":"10.2174\/1566523214666140522121427","volume":"14","author":"H Davtyan","year":"2014","unstructured":"Davtyan H, Hovakimyan A, Zagorski K, Davtyan A, Petrushina I, Agdashian D, Murthy V, Cribbs DH, Agadjanyan MG, Ghochikyan A. BTX AgilePulse(TM) system is an effective electroporation device for intramuscular and intradermal delivery of DNA vaccine. Curr Gene Ther. 2014;14:190\u20139.","journal-title":"Curr Gene Ther"},{"key":"556_CR20","doi-asserted-by":"publisher","first-page":"12721","DOI":"10.1523\/JNEUROSCI.3201-07.2007","volume":"27","author":"I Petrushina","year":"2007","unstructured":"Petrushina I, Ghochikyan A, Mktrichyan M, Mamikonyan G, Movsesyan N, Davtyan H, Patel A, Head E, Cribbs DH, Agadjanyan MG. Alzheimer\u2019s disease peptide epitope vaccine reduces insoluble but not soluble\/oligomeric a{beta} species in amyloid precursor protein transgenic mice. J Neurosci. 2007;27:12721\u201331.","journal-title":"J Neurosci"},{"key":"556_CR21","doi-asserted-by":"publisher","first-page":"4923","DOI":"10.1523\/JNEUROSCI.4672-12.2013","volume":"33","author":"H Davtyan","year":"2013","unstructured":"Davtyan H, Ghochikyan A, Petrushina I, Hovakimyan A, Davtyan A, Poghosyan A, Marleau AM, Movsesyan N, Kiyatkin A, Rasool S, et al. Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer\u2019s disease: prelude to a clinical trial. J Neurosci. 2013;33:4923\u201334.","journal-title":"J Neurosci"},{"key":"556_CR22","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/j.vaccine.2017.03.020","volume":"35","author":"H Davtyan","year":"2017","unstructured":"Davtyan H, Chen WW, Zagorski K, Davis J, Petrushina I, Kazarian K, Cribbs DH, Agadjanyan MG, Blurton-Jones M, Ghochikyan A. MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice. Vaccine. 2017;35:2015\u201324.","journal-title":"Vaccine"},{"key":"556_CR23","doi-asserted-by":"publisher","first-page":"13594","DOI":"10.1073\/pnas.0901402106","volume":"106","author":"M Blurton-Jones","year":"2009","unstructured":"Blurton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, Muller FJ, Loring JF, Yamasaki TR, Poon WW, Green KN, LaFerla FM. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A. 2009;106:13594\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"556_CR24","doi-asserted-by":"publisher","first-page":"E1316","DOI":"10.1073\/pnas.1525466113","volume":"113","author":"SE Marsh","year":"2016","unstructured":"Marsh SE, Abud EM, Lakatos A, Karimzadeh A, Yeung ST, Davtyan H, Fote GM, Lau L, Weinger JG, Lane TE, et al. The adaptive immune system restrains Alzheimer\u2019s disease pathogenesis by modulating microglial function. Proc Natl Acad Sci U S A. 2016;113:E1316\u201325.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"556_CR25","doi-asserted-by":"publisher","first-page":"22376","DOI":"10.1074\/jbc.M700088200","volume":"282","author":"G Mamikonyan","year":"2007","unstructured":"Mamikonyan G, Necula M, Mkrtichyan M, Ghochikyan A, Petrushina I, Movsesyan N, Mina E, Kiyatkin A, Glabe C, Cribbs DH, Agadjanyan MG. Anti-Abeta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils, but not the most toxic oligomers. J Biol Chem. 2007;282:22376\u201386.","journal-title":"J Biol Chem"},{"key":"556_CR26","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.4161\/hv.23875","volume":"9","author":"A Ghochikyan","year":"2013","unstructured":"Ghochikyan A, Davtyan H, Petrushina I, Hovakimyan A, Movsesyan N, Davtyan A, Kiyatkin A, Cribbs DH, Agadjanyan MG. Refinement of a DNA based Alzheimer\u2019s disease epitope vaccine in rabbits. Hum Vaccin Immunother. 2013;9:1002\u201310.","journal-title":"Hum Vaccin Immunother"},{"key":"556_CR27","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","volume":"39","author":"S Oddo","year":"2003","unstructured":"Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer\u2019s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409\u201321.","journal-title":"Neuron"},{"issue":"7","key":"556_CR28","doi-asserted-by":"publisher","first-page":"P1668","DOI":"10.1016\/j.jalz.2018.07.009","volume":"14","author":"Chad J. Swanson","year":"2018","unstructured":"Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Kramer L, Luthman J. Treatment of early AD subjects with BAN2401, an anti-A\u03b2 protofibril monoclonal antibody, significantly clears amyloid plaque and reduces clinical decline. Alzheimers Dement. 2018;14(7):1668.","journal-title":"Alzheimer's & Dementia"},{"key":"556_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41582-019-0205-1","volume":"15","author":"DJ Selkoe","year":"2019","unstructured":"Selkoe DJ. Alzheimer disease and aducanumab: adjusting our approach. Nat Rev Neurol. 2019;15:365\u20136.","journal-title":"Nat Rev Neurol"},{"key":"556_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2217\/imt-2018-0119","volume":"11","author":"F Panza","year":"2019","unstructured":"Panza F, Lozupone M, Dibello V, Greco A, Daniele A, Seripa D, Logroscino G, Imbimbo BP. Are antibodies directed against amyloid-beta (Abeta) oligomers the last call for the Abeta hypothesis of Alzheimer\u2019s disease? Immunotherapy. 2019;11:3\u20136.","journal-title":"Immunotherapy"},{"key":"556_CR31","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/acn3.469","volume":"4","author":"JJ Mo","year":"2017","unstructured":"Mo JJ, Li JY, Yang Z, Liu Z, Feng JS. Efficacy and safety of anti-amyloid-beta immunotherapy for Alzheimer\u2019s disease: a systematic review and network meta-analysis. Ann Clin Transl Neurol. 2017;4:931\u201342.","journal-title":"Ann Clin Transl Neurol"},{"key":"556_CR32","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2174\/187152709787847324","volume":"8","author":"R Tarawneh","year":"2009","unstructured":"Tarawneh R, Holtzman DM. Critical issues for successful immunotherapy in Alzheimer\u2019s disease: development of biomarkers and methods for early detection and intervention. CNS Neurol Disord Drug Targets. 2009;8:144\u201359.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"556_CR33","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2174\/187152709787847289","volume":"8","author":"T Wisniewski","year":"2009","unstructured":"Wisniewski T. AD vaccines: conclusions and future directions. CNS Neurol Disord Drug Targets. 2009;8:160\u20136.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"556_CR34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2174\/187152709787847315","volume":"8","author":"TA Kokjohn","year":"2009","unstructured":"Kokjohn TA, Roher AE. Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial. CNS Neurol Disord Drug Targets. 2009;8:88\u201397.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"556_CR35","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease. Nature. 2016;537:50\u20136.","journal-title":"Nature"},{"key":"556_CR36","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s12640-013-9398-z","volume":"24","author":"CG Parsons","year":"2013","unstructured":"Parsons CG, Danysz W, Dekundy A, Pulte I. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer\u2019s disease. Neurotox Res. 2013;24:358\u201369.","journal-title":"Neurotox Res"},{"key":"556_CR37","doi-asserted-by":"crossref","unstructured":"Van Bulck M, Sierra-Magro A, Alarcon-Gil J, Perez-Castillo A, Morales-Garcia JA. Novel approaches for the treatment of Alzheimer\u2019s and Parkinson\u2019s disease.\u00a0Int J Mol Sci. 2019;20(3):719.","DOI":"10.3390\/ijms20030719"},{"key":"556_CR38","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.brainresbull.2019.01.004","volume":"146","author":"Y Madav","year":"2019","unstructured":"Madav Y, Wairkar S, Prabhakar B. Recent therapeutic strategies targeting beta amyloid and tauopathies in Alzheimer\u2019s disease. Brain Res Bull. 2019;146:171\u201384.","journal-title":"Brain Res Bull"},{"key":"556_CR39","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.nicl.2017.09.016","volume":"17","author":"L Iaccarino","year":"2018","unstructured":"Iaccarino L, Tammewar G, Ayakta N, Baker SL, Bejanin A, Boxer AL, Gorno-Tempini ML, Janabi M, Kramer JH, Lazaris A, et al. Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer\u2019s disease. Neuroimage Clin. 2018;17:452\u201364.","journal-title":"Neuroimage Clin"},{"key":"556_CR40","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1021\/acschemneuro.9b00037","volume":"10","author":"T Tripathi","year":"2019","unstructured":"Tripathi T, Kalita P. Synergistic effect of amyloid-beta and tau disrupts neural circuits. ACS Chem Neurosci. 2019;10:1129\u201330.","journal-title":"ACS Chem Neurosci"},{"key":"556_CR41","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jalz.2013.12.003","volume":"10","author":"H Davtyan","year":"2014","unstructured":"Davtyan H, Ghochikyan A, Petrushina I, Hovakimyan A, Davtyan A, Cribbs DH, Agadjanyan MG. The MultiTEP platform-based Alzheimer\u2019s disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates. Alzheimers Dement. 2014;10:271\u201383.","journal-title":"Alzheimers Dement"},{"key":"556_CR42","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.neurobiolaging.2017.08.006","volume":"59","author":"H Davtyan","year":"2017","unstructured":"Davtyan H, Zagorski K, Petrushina I, Kazarian K, Goldberg NRS, Petrosyan J, Blurton-Jones M, Masliah E, Cribbs DH, Agadjanyan MG, Ghochikyan A. MultiTEP platform-based DNA vaccines for alpha-synucleinopathies: preclinical evaluation of immunogenicity and therapeutic potency. Neurobiol Aging. 2017;59:156\u201370.","journal-title":"Neurobiol Aging"},{"key":"556_CR43","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.3389\/fimmu.2017.01960","volume":"8","author":"T Fulop","year":"2017","unstructured":"Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, Witkowski JM, Franceschi C. Immunosenescence and Inflamm-aging as two sides of the same coin: friends or foes? Front Immunol. 2017;8:1960.","journal-title":"Front Immunol"},{"key":"556_CR44","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ymthe.2016.10.002","volume":"25","author":"I Petrushina","year":"2017","unstructured":"Petrushina I, Davtyan H, Hovakimyan A, Davtyan A, Passos GF, Cribbs DH, Ghochikyan A, Agadjanyan MG. Comparison of efficacy of preventive and therapeutic vaccines targeting the N terminus of beta-amyloid in an animal model of Alzheimer\u2019s disease. Mol Ther. 2017;25:153\u201364.","journal-title":"Mol Ther"},{"key":"556_CR45","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0165-5728(98)00098-8","volume":"88","author":"D Frenkel","year":"1998","unstructured":"Frenkel D, Balass M, Solomon B. N-terminal EFRH sequence of Alzheimer\u2019s beta-amyloid peptide represents the epitope of its anti-aggregating antibodies. J Neuroimmunol. 1998;88:85\u201390.","journal-title":"J Neuroimmunol"},{"key":"556_CR46","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jalz.2015.06.1884","volume":"11","author":"MG Agadjanyan","year":"2015","unstructured":"Agadjanyan MG, Petrovsky N, Ghochikyan A. A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer\u2019s disease. Alzheimers Dement. 2015;11:1246\u201359.","journal-title":"Alzheimers Dement"},{"key":"556_CR47","doi-asserted-by":"publisher","first-page":"9323","DOI":"10.1523\/JNEUROSCI.0293-11.2011","volume":"31","author":"C Wiessner","year":"2011","unstructured":"Wiessner C, Wiederhold KH, Tissot AC, Frey P, Danner S, Jacobson LH, Jennings GT, Luond R, Ortmann R, Reichwald J, et al. The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci. 2011;31:9323\u201331.","journal-title":"J Neurosci"},{"key":"556_CR48","first-page":"10","volume":"3","author":"R Vandenberghea","year":"2017","unstructured":"Vandenberghea R, Rivierec ME, Caputoc A, Sovagod J, Maguiree RP, Farlow M, Marottag G, Sanchez-Valleh R, Scheltensi P, Ryan JM, Graf A. Active Ab immunotherapy CAD106 in Alzheimer\u2019s disease: a phase 2b study. Alzheimer\u2019s Dementia. 2017;3:10\u201322.","journal-title":"Alzheimer\u2019s Dementia"},{"key":"556_CR49","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.trci.2017.03.005","volume":"3","author":"CY Wang","year":"2017","unstructured":"Wang CY, Wang PN, Chiu MJ, Finstad CL, Lin F, Lynn S, Tai YH, De Fang X, Zhao K, Hung CH, et al. UB-311, a novel UBITh((R)) amyloid beta peptide vaccine for mild Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2017;3:262\u201372.","journal-title":"Alzheimers Dement (N Y)"},{"key":"556_CR50","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","volume":"9","author":"JO Rinne","year":"2010","unstructured":"Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer\u2019s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363\u201372.","journal-title":"Lancet Neurol"},{"key":"556_CR51","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2217\/imt.10.80","volume":"2","author":"F Panza","year":"2010","unstructured":"Panza F, Frisardi V, Imbimbo BP, D'Onofrio G, Pietrarossa G, Seripa D, Pilotto A, Solfrizzi V. Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer\u2019s disease. Immunotherapy. 2010;2:767\u201382.","journal-title":"Immunotherapy"},{"key":"556_CR52","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12868-018-0446-8","volume":"19","author":"Y Sakakibara","year":"2018","unstructured":"Sakakibara Y, Sekiya M, Saito T, Saido TC, Iijima KM. Cognitive and emotional alterations in App knock-in mouse models of Abeta amyloidosis. BMC Neurosci. 2018;19:46.","journal-title":"BMC Neurosci"},{"key":"556_CR53","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/alzrt182","volume":"5","author":"SJ Webster","year":"2013","unstructured":"Webster SJ, Bachstetter AD, Van Eldik LJ. Comprehensive behavioral characterization of an APP\/PS-1 double knock-in mouse model of Alzheimer\u2019s disease. Alzheimers Res Ther. 2013;5:28.","journal-title":"Alzheimers Res Ther"},{"key":"556_CR54","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nn.3697","volume":"17","author":"T Saito","year":"2014","unstructured":"Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, Iwata N, Saido TC. Single App knock-in mouse models of Alzheimer\u2019s disease. Nat Neurosci. 2014;17:661\u20133.","journal-title":"Nat Neurosci"},{"key":"556_CR55","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.nlm.2016.07.001","volume":"135","author":"A Masuda","year":"2016","unstructured":"Masuda A, Kobayashi Y, Kogo N, Saito T, Saido TC, Itohara S. Cognitive deficits in single App knock-in mouse models. Neurobiol Learn Mem. 2016;135:73\u201382.","journal-title":"Neurobiol Learn Mem"},{"key":"556_CR56","doi-asserted-by":"publisher","first-page":"12754","DOI":"10.1074\/jbc.RA119.009487","volume":"294","author":"T Saito","year":"2019","unstructured":"Saito T, Mihira N, Matsuba Y, Sasaguri H, Hashimoto S, Narasimhan S, Zhang B, Murayama S, Higuchi M, Lee VMY, et al. Humanization of the entire murine Mapt gene provides a murine model of pathological human tau propagation. J Biol Chem. 2019;294:12754\u201365.","journal-title":"J Biol Chem"},{"key":"556_CR57","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.15252\/embj.201797397","volume":"36","author":"H Sasaguri","year":"2017","unstructured":"Sasaguri H, Nilsson P, Hashimoto S, Nagata K, Saito T, De Strooper B, Hardy J, Vassar R, Winblad B, Saido TC. APP mouse models for Alzheimer\u2019s disease preclinical studies. EMBO J. 2017;36:2473\u201387.","journal-title":"EMBO J"},{"key":"556_CR58","doi-asserted-by":"publisher","first-page":"5407","DOI":"10.1016\/j.vaccine.2012.06.009","volume":"30","author":"DL Gordon","year":"2012","unstructured":"Gordon DL, Sajkov D, Woodman RJ, Honda-Okubo Y, Cox MM, Heinzel S, Petrovsky N. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1\/2009 pandemic influenza vaccine containing Advax polysaccharide adjuvant. Vaccine. 2012;30:5407\u201316.","journal-title":"Vaccine"},{"key":"556_CR59","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1016\/j.vaccine.2014.09.034","volume":"32","author":"D Gordon","year":"2014","unstructured":"Gordon D, Kelley P, Heinzel S, Cooper P, Petrovsky N. Immunogenicity and safety of Advax, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled phase 1 study. Vaccine. 2014;32:6469\u201377.","journal-title":"Vaccine"},{"key":"556_CR60","doi-asserted-by":"publisher","first-page":"P158","DOI":"10.1186\/1939-4551-6-S1-P158","volume":"6","author":"R Heddle","year":"2013","unstructured":"Heddle R, Russo P, Petrovsky N, Hanna R, Smith A. Immunotherapy \u2013 2076. A controlled study of delta inulin-adjuvanted honey bee venom immunotherapy. World Allergy Organ J. 2013;6:P158.","journal-title":"World Allergy Organ J"},{"issue":"44","key":"556_CR61","doi-asserted-by":"publisher","first-page":"5920","DOI":"10.1016\/j.vaccine.2015.09.030","volume":"33","author":"Nikolai Petrovsky","year":"2015","unstructured":"Petrovsky N, Cooper PD. Advax, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety. Vaccine. 2015;33(44):5920\u20136.","journal-title":"Vaccine"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-019-0556-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-019-0556-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-019-0556-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T19:24:45Z","timestamp":1608060285000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-019-0556-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["556"],"URL":"https:\/\/doi.org\/10.1186\/s13195-019-0556-2","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"21 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal studies are conducted in accordance with the NIH, American Physiological Society, and University of California, Irvine Animal Care Guidelines. The University of California, Irvine, animal assurance number is A3416-01.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MGA and AG are co-founders of Capo Therapeutics that licensed MultiTEP vaccine platform technology from the Institute for Molecular Medicine. NP is a founder of Vaxine that developed Advax<sup>CpG<\/sup> adjuvant. The remaining authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}